CURRENT STATE OF SAFETY RESEARCH IN PEDIATRIC RHEUMATOLOGY
In the late 1990s, the first immunomodulatory products for rheumatic diseases were introduced, revolutionizing care for adults and children who have inflammatory arthritis. [1] [2] [3] The proven effectiveness of tumor necrosis factor (TNF) inhibitors fueled the development of other products targeting cytokines and cellular receptors involved in the pathophysiology of various inflammatory and autoimmune diseases. Although the benefits of targeted immunomodulatory products are clear, the short-and long-term risks in children and adolescents are uncertain. These risks are particularly important for children, given their possible impact on the developing immune system and the potential for life-long exposure. In addition, the pharmacokinetics of drugs often differ in children, 4 so safety information collected in adults may not be generalizable to children.
In November 2009, the US Food and Drug Administration (FDA) placed a Boxed Warning for TNF inhibitors, informing prescribers of malignancies in children and young adults. The warning was based on analysis of voluntary post-marketing reports of malignancies in pediatric patients receiving TNF inhibitors for various conditions. 5 However, voluntary reporting systems are limited owing to event underreporting, inadequate clinical detail, no knowledge about the total number of patients exposed (denominator) necessary to calculate an incidence rate, and the lack of a relevant comparator group of unexposed children. The FDA Boxed Warning understandably caused alarm among parents of children taking TNF inhibitors and may have prompted decisions not to use TNF inhibitors, trading an effective treatment with a potential yet uncertain risk for cancer for less effective treatments carrying no perceived risk. Subsequent studies have demonstrated an increased baseline rate of malignancy among all children who have juvenile idiopathic arthritis (JIA) compared with the general population even without biologic exposure. [6] [7] [8] 9 However, other studies have not revealed increased malignancy risk in JIA, highlighting the need for more robust longer-term studies with active comparators rather than historical controls. 10 Other events of interest in children treated with immunomodulatory products include opportunistic infections, lupus or lupuslike illnesses, demyelinating diseases, pulmonary hypertension, inflammatory bowel disease, and uveitis. [11] [12] [13] [14] Historically children were excluded from clinical trials and most products lacked adequate pediatric safety and efficacy data. However, appropriate labeling of clinical safety and efficacy data for children has improved in the United States over the last decade through a series of federal legislative actions, culminating in the permanent authorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act (PREA) under theFDASafetyandInnovationActof 2012. [15] [16] [17] [18] [19] European pediatric legislation has also developed in parallel with that in the United States. These legislative developments are summarized in Fig 1. Under this legislation, a pediatric assessment is required for all drug or biological product applications or supplemental applications for a new active ingredient, new indication, new dosage form,newdosingregimen, ornewrouteof administration. 20 Therefore, drugs and biological products seeking approval for the treatment of adult rheumatoid arthritis as a new indication would be subject to PREA. Importantly, pediatric studies can only be required under PREA for the specific reasons listed above. However, sponsors may receive additional marketing exclusivity for pediatric conditions that may not occur in adults through the issuance of a Written Request under the Best Pharmaceuticals for Children Act. Unique subpopulations such as systemic JIA with systemic involvement and few joints may also be put forward for FDA approval. The recent Biologics License Application approval of tocilizumab in systemic JIA (www. clinicaltrials.gov identifier NCT00642460) is one such example.
The pivotal phase 3 trials of biologic agents in polyarticular-course JIA have involved relatively small patient populations because of the low prevalence of JIA. In addition, the use of novel trial designs in these studies, such as the randomized withdrawal design, limit placebo exposure, 2,21-23 such that serious and/or uncommon adverse events cannot reliably be detected in these registration trials. Most children are exposed to multiple agents over time, such that pinpointing adverse event association with a single product is problematic. Lastly, as previously described, having rheumatic diseases may predispose children to increased risks for adverse events irrespective of therapy, 6, 24 although the magnitude of this baseline risk is poorly quantified.
The long-term safety of immunomodulatory products in JIA is currently monitored in 3 ways: open-label, long-term extension studies of randomized controlled trials; passive adverse event surveillance systems; and sponsor-led product-specific observational registries that have traditionally fulfilled industry post-marketing commitments and requirements. Each has significant limitations as outlined in Table 1 . Although the FDA' s recently implemented Sentinel Program will significantly improve current passive surveillance methods through actively surveying diverse data holders, the consolidated safety registry approach will provide richer clinical data and insure longer follow-up of patients beyond what is available in insurance claims to allow better adjustment for potential confounders, including disease severity.
These limitations are illustrated in the etanercept post-marketing registry in polyarticular course JIA, 25 [abatacept]), are fulfilling post-marketing requirements and commitments for single-product registries with 10 years of follow-up and greater numbers of participants exposed to the product compared with the etanercept registry; however, the high discontinuation rates seen over just 3 years in the etanercept registry 25 as well as the limited numbers of available participants for competing registries are likely to lead to vanishingly small numbers of participants over the life of each product-specific study.
The lack of comprehensive pediatric safety data on immunomodulatory products is a hardship for both families and health care providers when weighing the risks and benefits of powerful products. With large numbers of immunomodulatory products under study in current or planned clinical trials, clinical investigators will be unable to meet enrollment targets for multiple, single-product registries. Biopharmaceutical companies compete for the same pool of patients and investigators globally with significant overlap of the collected information for each product-specific registry. Interpretation of collected data is complicated by serial use of different immunomodulatory products by participants over the duration of each registry, as well as the use of concomitant medications. Clearly a model that better meets the public mandate for efficient and relevant safety surveillance of these agents is urgently needed.
A MODEL FOR SAFETY SURVEILLANCE: CONSOLIDATED SAFETY REGISTRY
Over the past 3 years, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) 26 28 and further expanded in a stakeholder meeting held June 2011, leading to the development of the CARRA-Consolidated Safety Registry (CARRA-CoRe).
A consolidated disease-based safety registry can address many limitations of product-specific registries as shown in Table 2 . For patients, families, clinicians, and biopharmaceutical companies, a consolidated safety registry offers the opportunity to more efficiently evaluate the risk/benefit ratio of treatments with less redundant information, and reflects treatment usage within the context of usual clinical care. Importantly, the consolidated safety registry allows for a more scientifically robust approach to collecting safety data on products of interest while fulfilling biopharmaceutical companies' post-marketing requirements at the same or lower cost. The following sections describe critical elements of the model and the accompanying development plan and protocol for CARRA-CoRe. Scientifically sound and efficient approach to meet postmarketing requirements and commitments for registries Improved assessment of the risk/benefit ratio of treatment options for patients, families, and providers Ability to compare multiple exposed and unexposed groups to more accurately analyze the strength of the association of adverse events to products Improved ability to understand contribution of disease course and severity to adverse events and outcomes Ability to incorporate patient-and family-centered goals and patient-reported outcomes Engagement of patients and families in design and governance of the consolidated safety registry Patients, families, and clinicians have input into the evaluation of the risk/benefit ratio of treatment options Improved patient and family trust in immunomodulatory products and the pharmaceutical industry owing to transparent governance and scientific oversight CARRA' s scientific committee structure continuously drives a diverse project portfolio that currently includes 27 active projects and multiple completed studies and trials. 26 The CARRA Registry was initially funded by an NIH American Recovery and Reinvestment Act of 2009 award with additional support from AF and Friends of CARRA (a nonprofit parent run organization supporting CARRA). The CARRA Registry is based on a 21CFR11compliant electronic data entry foundation with a modular, flexible, extensible research data storage and framework. 29, 30 Registry enrollment started in May 2010 and includes longitudinal data on all major pediatric rheumatic diseases from 60 US pediatric rheumatology centers with the goal of following at least 10 000 participants for over 10 years. Table 3 shows enrollment in the CARRA Registry as of February 2013. The establishment of CARRA-CoRe will build on the existing infrastructure of CARRA and the CARRA Registry, which will necessitate expansion of the existing registry data collection to include more extensive safety surveillance and detailed medication use. Figure 2 describes the data architecture of the CARRA Registry and CARRA-CoRe, and Table 4 explains the data flow and the elements in the figure.
The CARRA-CoRe protocol includes approaches to general data collection, management, and analysis, with enhancements if requested by industry partners. The overall approach includes initial online electronic data capture with eventual direct electronic health record transfer. Follow-up occurs twice yearly (approximately every 6 months). Active surveillance is performed either at the site or centrally. The DCRI will actively survey patients no longer connected with a site or lost to follow-up. Serious adverse events and prespecified important medical events are collected and centrally categorized using the Medical Dictionary for Regulatory Activities. Incoming data are monitored for irregularities that may prompt "for cause" site monitoring at any time in addition to periodic routine on-site monitoring. For each product of interest, methodologic and clinical factors will be considered in selecting the most appropriate study design (cohort, case control, or case only design), defining study populations and comparators, assessing and categorizing exposure status over time, accounting for potential confounders, and considering effect modifications by patient factors. After carefully designing studies for specific products of interest, the best analytical approaches will be chosen, including multivariable regression, propensity scoring, and methods to account for time-varying confounding such as marginal structural modeling.
CARRA-CORE GOVERNANCE AND SCIENTIFIC OVERSIGHT
The proposed governance plan (Fig 3) ensures representation by all relevant stakeholders and optimizes scientific collaboration while maintaining scientific independence. Key elements that form the foundation for a robust governance plan are shown in groups and family/patient representatives who review and advise the Steering Committee regarding general principles and progress. CARRA-CoRe' s Data Coordinating Center (DCRI) provides significant expertise in contracting, research coordinator support, regulatory compliance, site management, registries and large databases, and safety monitoring and reporting. DCRI has executed rapid start agreements with the current CARRA Registry sites. DCRI has an established administrative center for managing subject verification as well as long-term follow-up. It verifies that a valid informed consent exists for each subject, maintains a central repository of contact information that is firewalled from the CARRA-CoRe clinical database to protect patient confidentiality ("honest broker"), 31 and manages a centralized contact center for longterm follow-up that will be especially important as participants transfer out from pediatric to adult medical services. Data access will be governed by the rigorous CARRA Data and Sample Sharing policies and overseen by the SOC. Industry partners will have full access to data query outputs and datasets for their respective products along with input into analysis plans in accordance with the policies and procedures of the SOC and the ISAC. The financial model proposes public and nonprofit investments in database infrastructure and private industry funding for registry operations with additional joint investments in research and development. Development of the database architecture and infrastructure was enabled by awards from the NIH and nonprofit organizations. Eachindustryfunder will contribute to the ongoing yearly operational costs of CARRA-CoRe and will receive standard data outputs in return. In addition, nonprofit or governmental agencies may contribute to operational costs and sponsor specific data requests of CARRA-CoRe. Industry funders may enter into contracts to meet postmarketing requirements or other organizational objectives. With participation bymultiple sponsors, abenefit toindustry funders is the ability to include new therapeutic agents without significant additional infrastructure investment. To insure sustainability over time, critical design elements of the CARRA-CoRe public-private partnership include a single point of negotiations based on the existing rapid start agreements of the CARRA Registry consortium, and policies addressing intellectual property, antitrust issues, and conflict resolution. Industry funders will benefit significantly from participation in a public-private partnership through operational efficiencies gained by using a high-functioning centralized network, elimination of 
SUSTAINABILITY OF CARRA-CORE

Data entry and imports
The CARRA Registry has for FDA 21CFR11 compliant site data entry using an electronic data capture system and, at certain sites, electronic health record data transfer. Subjects are consented at each site. Contact information and copies of informed consents are maintained in the Consent and Contact Database that is managed by the Long-Term Followup Group at the DCRI. Access to clinical data and contact data are separated by a Personal Identifiers Firewall (at both organizational and electronic levels) to ensure privacy and protect the usage of contact and personal health information. Patient-reported outcomes and surveys are collected and entered into the electronic data system or entered directly by subjects.
Data exports
Imported data are securely routed to site-specific i2b2 datamarts corresponding to the originating sites. Multiple virtual i2b2 databases are hosted on a central i2b2 server "farm,"
allowing scalability to add sites, other sources of data entry, or specific projects such as CARRA-CoRe. Permissioned sharing of data is governed through the Shared Health
Research Information Network. The CARRA Registry i2b2-Self Scaling Registry Query Aggregator and User
Interface permits each site to query its own CARRA Registry data. Permissioned investigators can perform network queries to access and analyze aggregated data across 2 or more network sites. CARRA-CoRe has a virtual i2b2 datamart incorporating data imports from the CARRA Registry with additional CARRA-CoRe-specific fields. Additional data from review of medical records for serious adverse events or prespecified important medical events are entered into the CARRA-CoRe datamart. Additional linked data sources are added as appropriate to the CARRA-CoRe requirements. CARRA-CoRe queries can provide multiple opportunities for primary and secondary analyses relevant to pharmacoepidemiology, adverse events, medication safety, and other areas of interest.
competition for participant enrollment, improved ability to accurately assess adverse events, and improved public trust in product safety information.
FUTURE CONSIDERATIONS
Moving forward requires endorsement of a shared commitment to the sustainability and success of CARRA-CoRe by public and private nonprofit and for-profit stakeholders. Industry investment in CARRA-CoRe would ideally replace current expenditures on product-specific safety registries, which are resource-intensive and are unable to yield scientifically rigorous long-term safety information of immunomodulatory agents in children who have rheumatic diseases. The FDA issued a statement that a consolidated safety registry such as CARRA-CoRe (previously called JIA-CoRe) could fulfill postmarketing requirements and replace the current use of product specific registries: Essential to the success of CARRA-CoRe is the continued engagement of pediatric rheumatologists and their commitment toalong-termlongitudinalregistry.Oneof the benefits of CARRA-CoRe and its links to the CARRA Registry is the research opportunities already available to CARRA investigators who have a vested interest in improving outcomes of children who have rheumatic diseases. The engagement of CARRA investigators is demonstrated by the current achievements of the CARRA Registry, which has successfully enrolled over 8211 participants from 60 sites as of February 2013 ( Table 2) . Data from the registry has already resulted in multiple national presentations and publications. 24, [32] [33] [34] CARRA-CoRe can also provide realistic estimates of available participants to inform the appropriate design of pre-and postmarketing studies. Importantly, industry funders can use CARRA-CoRe and the CARRA Registry to address additional questions of interest and to identify other areas of potential collaboration with the pediatric rheumatology community. Coordination with similar efforts ongoing in Europe is underway to facilitate harmonization of adverse event data for analysis of post-marketing safety on a global scale. There are existing European national JIA safety registries that CARRA-CoRe organizational structure. The CARRA-CoRe structure is designed to insure scientific independence through the Scientific Oversight Committee, while the Steering Committee is responsible for strategy, operational oversight, resources, involvement of industry sponsors, and input from Advisory Committees.
continue to collect data, and the Paediatric Rheumatology European Society along with the Pediatric Rheumatology International Trials Organization has launched PHARMACHILD, a JIA diseasespecific pharmacovigilance registry for biologic products, supported by the European Union (7th Framework Program) and pharmaceutical industry. Opportunities to use mapping ontologies to combine data from the various registries are also being explored.
CONCLUSIONS
A consolidated safety registry provides many advantages over current methods of pharmacosurveillance for immunomodulatory products used to Fair and transparent policies and procedures developed by the SOC with input from industry govern analyses of serious adverse events in the context of multiple exposures, risk windows, and other approaches. Long-term follow-up Implementing processes and procedures to follow participants who relocate or transfer to adult care
The Long-Term Follow-Up Group within the DCRI Clinical and Data Coordinating Center manages a centralized communication repository, including confidential contact information for participants. Efforts to harmonize a validated set of outcome tools and patient-reported outcome measures that can be used across the lifespan are underway. In addition, the protected contact repository will facilitate potential future linkage to large administrative and billing databases including the Centers of Medicare and Medicaid Services, pharmacy databases, insurance databases, cancer registries, death index, and other registries and resources.
Patient confidentiality
Assuring the highest level of personal health information protection
Participants' personal health information is sequestered from clinical data at the sites or by the Long-Term Follow-Up Group (Honest Broker) 31 
Data access and sharing
Insuring responsible and transparent stewardship of data analysis and dissemination and publication of results
Policies and procedures are under development to govern data access, analysis, utilization, dissemination and publication of results to guarantee meeting safety and regulatory requirements and responsible conduct of research.
Management of intellectual property and antitrust issues
Balancing protection of public safety with intellectual property interests and antitrust issues
The Steering Committee is responsible for overseeing potential conflicts regarding ethical and regulatory reporting of safety issues with intellectual property or antitrust issues. a The FDA agreed to this monitoring approach in concept, and the approach is generally consistent with that described in the FDA' s draft monitoring guidance issued in August 2011 and a letter from the Division of Pulmonary, Allergy, and Rheumatology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, FDA, regarding CARRA-CoRe monitoring plan dated December 21, 2010. treat pediatric rheumatic diseases. By collaborating with industry partners, advocacy groups, DCRI, and government agencies such as the FDA, NIH, and European Medicines Agency, a consolidated safety registry such as CARRA-CoRe can overcome barriers to markedly improve the ability to capture and understand long-term and rare adverse events. This critical knowledge will translate directly into better medication usage and improved patient care and safety. Ultimately this model can be a powerful and efficient tool to understand rare and serious adverse events as well as events with long latency in other childhood and adult chronic and complex diseases.
